Genovate Biotechnology Co Ltd (4130) - Net Assets
Based on the latest financial reports, Genovate Biotechnology Co Ltd (4130) has net assets worth NT$1.38 Billion TWD (≈ $43.49 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.51 Billion ≈ $47.46 Million USD) and total liabilities (NT$126.05 Million ≈ $3.97 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 4130 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.38 Billion |
| % of Total Assets | 91.63% |
| Annual Growth Rate | -4.22% |
| 5-Year Change | 0.11% |
| 10-Year Change | -38.63% |
| Growth Volatility | 9.46 |
Genovate Biotechnology Co Ltd - Net Assets Trend (2015–2025)
This chart illustrates how Genovate Biotechnology Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Genovate Biotechnology Co Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual net assets of Genovate Biotechnology Co Ltd from 2015 to 2025. For live valuation and market cap data, see how much is Genovate Biotechnology Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.38 Billion ≈ $43.49 Million |
-4.75% |
| 2024-12-31 | NT$1.45 Billion ≈ $45.66 Million |
-1.34% |
| 2023-12-31 | NT$1.47 Billion ≈ $46.27 Million |
+4.11% |
| 2022-12-31 | NT$1.41 Billion ≈ $44.45 Million |
+2.32% |
| 2021-12-31 | NT$1.38 Billion ≈ $43.44 Million |
-3.30% |
| 2020-12-31 | NT$1.43 Billion ≈ $44.93 Million |
+1.26% |
| 2019-12-31 | NT$1.41 Billion ≈ $44.37 Million |
-9.93% |
| 2018-12-31 | NT$1.56 Billion ≈ $49.26 Million |
-2.26% |
| 2017-12-31 | NT$1.60 Billion ≈ $50.40 Million |
-28.88% |
| 2016-12-31 | NT$2.25 Billion ≈ $70.86 Million |
+5.88% |
| 2015-12-31 | NT$2.12 Billion ≈ $66.93 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genovate Biotechnology Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47.4% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$45.68 Million | 3.31% |
| Other Components | NT$1.33 Billion | 96.69% |
| Total Equity | NT$1.38 Billion | 100.00% |
Genovate Biotechnology Co Ltd Competitors by Market Cap
The table below lists competitors of Genovate Biotechnology Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ekter SA
AT:EKTER
|
$98.38 Million |
|
Agile Group Holdings Limited
F:A8P
|
$98.38 Million |
|
ABC Taiwan Electronics
TWO:3236
|
$98.42 Million |
|
DRTECH Corporation
KQ:214680
|
$98.45 Million |
|
Markforged Holding Corp
NYSE:MKFG
|
$98.34 Million |
|
Canadian Net Real Estate Investment Trust
V:NET-UN
|
$98.34 Million |
|
Pasofino Gold Limited
V:VEIN
|
$98.33 Million |
|
Thai Optical Group Public Company Limited
BK:TOG
|
$98.31 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genovate Biotechnology Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,449,138,000 to 1,380,320,000, a change of -68,818,000 (-4.7%).
- Net income of 11,682,000 contributed positively to equity growth.
- Dividend payments of 11,152,000 reduced retained earnings.
- Other factors decreased equity by 69,348,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$11.68 Million | +0.85% |
| Dividends Paid | NT$11.15 Million | -0.81% |
| Other Changes | NT$-69.35 Million | -5.02% |
| Total Change | NT$- | -4.75% |
Book Value vs Market Value Analysis
This analysis compares Genovate Biotechnology Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.34x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.84x to 2.34x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$14.91 | NT$27.45 | x |
| 2018-12-31 | NT$14.57 | NT$27.45 | x |
| 2019-12-31 | NT$13.32 | NT$27.45 | x |
| 2020-12-31 | NT$13.48 | NT$27.45 | x |
| 2021-12-31 | NT$12.78 | NT$27.45 | x |
| 2022-12-31 | NT$12.90 | NT$27.45 | x |
| 2023-12-31 | NT$12.38 | NT$27.45 | x |
| 2024-12-31 | NT$12.34 | NT$27.45 | x |
| 2025-12-31 | NT$11.75 | NT$27.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genovate Biotechnology Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.85%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.37%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.09x
- Recent ROE (0.85%) is below the historical average (2.35%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 2.19% | 9.73% | 0.19x | 1.18x | NT$-165.94 Million |
| 2016 | 1.74% | 9.54% | 0.16x | 1.18x | NT$-185.71 Million |
| 2017 | 9.31% | 36.49% | 0.20x | 1.28x | NT$-11.00 Million |
| 2018 | 3.70% | 12.69% | 0.26x | 1.11x | NT$-98.50 Million |
| 2019 | 2.42% | 7.31% | 0.30x | 1.12x | NT$-106.77 Million |
| 2020 | 2.72% | 8.19% | 0.30x | 1.10x | NT$-103.87 Million |
| 2021 | 0.03% | 0.09% | 0.29x | 1.10x | NT$-137.51 Million |
| 2022 | -0.87% | -2.81% | 0.28x | 1.11x | NT$-153.41 Million |
| 2023 | 2.00% | 5.55% | 0.33x | 1.09x | NT$-117.54 Million |
| 2024 | 1.77% | 5.03% | 0.32x | 1.10x | NT$-119.22 Million |
| 2025 | 0.85% | 2.37% | 0.33x | 1.09x | NT$-126.35 Million |
Industry Comparison
This section compares Genovate Biotechnology Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,827,537,556
- Average return on equity (ROE) among peers: 3.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genovate Biotechnology Co Ltd (4130) | NT$1.38 Billion | 2.19% | 0.09x | $98.37 Million |
| Apex Biotechnology Corp (1733) | $1.35 Billion | 29.84% | 0.15x | $89.90 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.42 Billion | 0.26% | 0.72x | $188.76 Million |
| Panion & BF Biotech Inc (1760) | $2.01 Billion | 9.08% | 0.54x | $184.23 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $3.36 Billion | 1.58% | 0.42x | $68.46 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $996.24 Million | 6.00% | 0.56x | $99.61 Million |
| Level Biotechnology (3118) | $522.28 Million | 13.08% | 0.40x | $34.35 Million |
| GenMont Biotech Inc (3164) | $290.14 Million | -2.84% | 0.08x | $47.96 Million |
| Medigen Biotechnology (3176) | $3.54 Billion | -16.06% | 0.36x | $144.62 Million |
| Sagittarius Life Science (3205) | $965.47 Million | -11.83% | 0.10x | $119.60 Million |
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more